Open AccessRapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies
Author(s) -
Brian Kim,
Jonathan I. Silverberg,
Sonja Ständer,
Gil Yosipovitch,
Eric L. Simpson,
Marco DiBonaventura,
Urs Kerkmann,
Saleem A. Farooqui,
Pinaki Biswas,
Hernán Valdez,
Michael C. Cameron
Publication year - 2021
Publication title -
dermatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 56
eISSN - 2162-5220
pISSN - 1710-3568
DOI - 10.1097/der.0000000000000770
Subject(s) - medicine , atopic dermatitis , placebo , antipruritic , janus kinase inhibitor , eczema area and severity index , dermatology , randomized controlled trial , janus kinase , receptor , pathology , alternative medicine
Itch, the most bothersome symptom in atopic dermatitis, is largely mediated by pruritogenic cytokines via Janus kinase 1 signaling in cutaneous sensory neurons.